InfuSystem Holdings Inc

InfuSystem operates with a debt-to-equity ratio of 0.34 and a current ratio of 1.8, indicating moderate leverage and adequate short-term liquidity. The company's price-to-book ratio of 3.09 and price-to-tangible-book ratio of 3.09 suggest market valuation exceeds book value, while the enterprise value to EBITDA ratio of 16.24 indicates a premium to earnings. Return on equity of 11.56% and return on assets of 6.59% show strong profitability relative to equity but moderate efficiency in asset utilization. The company's operating margin of 8.31% (calculated from operating income of $11.92M on revenue of $143.44M) and net margin of 4.62% (calculated from net income of $6.63M) are below the industry median for medical equipment and services providers, which typically report operating margins between 12-18%. Gross margin of 56.0% (calculated from gross profit of $80.30M) is in line with industry norms for home healthcare services. InfuSystem's revenue is concentrated in the United States, with 100% of total revenue derived from domestic operations. The company operates through a single business segment focused on home infusion therapy services, with no material geographic or product diversification. The company's revenue growth outlook for the current fiscal year is 4.5% year-over-year, with a 6.2% growth projection for the following year. This aligns with the 3-7% growth range typical for home healthcare providers, though the company's free cash flow of $11.24M and operating cash flow of $24.41M provide strong financial flexibility for reinvestment. The risk assessment identifies liquidity as a medium concern due to negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no material share issuance expected in the near term. The company's capital structure includes $19.63M in long-term debt and $3.19M in cash and equivalents. Recent investor relations data shows strong analyst sentiment, with a mean price target of $14.90 and a median price target of $15.00, representing a 70% upside from the current market price of $8.77. The mean recommendation of 1.80 (on a 1-5 scale) indicates a strong buy consensus among analysts.